First-quarter 1996 group sales at Germany's Bayer improved 4% to 12.2 billion Deutschemarks ($7.99 billion), but this rise was almost entirely due to the first-time inclusion of ABS plastics, acquired from Monsanto. Group income before tax was up 14% at 140 million marks, and net earnings rose 19% to 110 million marks.
Health care sales, at 2.89 billion marks ($1.89 billion), were 3.1% higher in D-mark terms and showed an increase of 4.4% in local currencies. Bayer AG turnover rose 0.4% to 5.04 billion marks, and produced pretax earnings of 680 million marks, a rise of 19.2%. Within the group, particularly good sales performance was seen in North America, up 16%, while growth in Europe was just 1%. Bayer says the current year has got off to a good start; it is confident of achieving pretax earnings growth of 10% planned for the full year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze